%PDF-1.4
%
31 0 obj
<>
endobj
28 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-06-08T14:59:42Z
2024-03-28T18:21:31-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T18:21:31-07:00
application/pdf
Heather
2003-418.july
uuid:1f462392-1dd2-11b2-0a00-5209275d6100
uuid:1f462395-1dd2-11b2-0a00-aa0000000000
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 11 0 R/Type/Page>>
endobj
102 0 obj
[106 0 R]
endobj
103 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.1266 Tw 10 0 0 10 54 713.1616 Tm
[(development of CMV)-358.9 (diseases in patients with inflamma-)]TJ
0.1297 Tw 0 -1.2 TD
(tory CTD)Tj
0 Tw 6.5 0 0 6.5 93.9001 704.4616 Tm
(2-6)Tj
0.1297 Tw 10 0 0 10 102.563 701.1616 Tm
(. Using a PCR technique, we observed a high)Tj
0.1109 Tw -4.8563 -1.2 Td
[(incidence of CMV)-343.3 (reactivation in patients with inflamma-)]TJ
0.1794 Tw T*
[(tory CTD. )54.8 (Although the patient group was heterogenous,)]TJ
0.0287 Tw T*
(our results strongly suggest that patients with inflammatory)Tj
-0.0239 Tw T*
[(CTD who are under)17.7 (going immunosuppressive therapy are at)]TJ
0.02229 Tw T*
[(risk for CMV)-254.6 (reactivation. )17.7 (The previously reported patients)]TJ
0.3096 Tw T*
[(with CMV)-541.9 (diseases associated with inflammatory CTD)]TJ
0.00481 Tc 0.3701 Tw T*
[(were under)17.7 (going intensive immunosuppressive therapy)64.6 (,)]TJ
-0.00011 Tc 0.1049 Tw T*
[(except for a single case of disseminated CMV)-337.2 (disease not)]TJ
0.3638 Tw T*
(associated with immunosuppressive therapy)Tj
0 Tc 0 Tw 6.5 0 0 6.5 241.247 596.4615 Tm
(19)Tj
-0.00011 Tc 0.3461 Tw 10 0 0 10 247.7469 593.1616 Tm
[(. Thus )-17.7 (we)]TJ
0.0033 Tc 0.3716 Tw -19.3747 -1.2 Td
[(investigated the incidence of CMV)-607.3 (reactivation in 12)]TJ
-0.00011 Tc 0.05659 Tw T*
(patients with inflammatory CTD before initiating immuno-)Tj
-0.0183 Tw T*
[(suppressive therapy in order to clarify the ef)17.7 (fects of immune)]TJ
0.0293 Tw T*
(deficits associated with these diseases and immunosuppres-)Tj
0.2971 Tw T*
[(sive therapy on the susceptibility to CMV)-529.4 (reactivation.)]TJ
0.14571 Tw T*
[(CMV)-378 (reactivation was detected in none of these patients.)]TJ
0.0733 Tw T*
(These findings strongly suggested that immunosuppressive)Tj
0.0247 Tw T*
[(therapy plays a crucial role in susceptibility to CMV)-257 (reacti-)]TJ
0.02499 Tw T*
(vation in patients with inflammatory CTD.)Tj
0.0569 Tw 1.2 -1.2 Td
[(In addition, CMV)-289.2 (has been reported to af)17.7 (fect the course)]TJ
0.0882 Tw -1.2 -1.2 Td
(of inflammatory CTD, namely via exacerbation or flare of)Tj
0.0199 Tc 0.3692 Tw T*
(the CTD)Tj
0 Tw 6.5 0 0 6.5 93.8058 452.4616 Tm
(20,21)Tj
0.3692 Tw 10 0 0 10 109.0805 449.1616 Tm
[(. )54.9 (Although some possibilities have been)]TJ
-0.00011 Tc 0.2386 Tw -5.5081 -1.2 Td
[(suggested, including cross-reactivity between CMV)-470.9 (anti-)]TJ
0.1908 Tw T*
(gens and autologous antigens, the mechanism underlying)Tj
0.1283 Tw T*
[(the relationship between CMV)-360.6 (and the activity of inflam-)]TJ
0.0578 Tw T*
[(matory CTD has not yet been fully elucidated. However)39.6 (, it)]TJ
0.36459 Tw T*
[(is suggested that therapy against CMV)-597 (reactivation in)]TJ
0.00079 Tw T*
(patients with inflammatory CTD may modify the activity of)Tj
0.02499 Tw T*
(the CTD itself.)Tj
0.037 Tw 1.2 -1.2 Td
[(W)79.9 (e conclude that patients with inflammatory connective)]TJ
0.3438 Tw -1.2 -1.2 Td
[(tissue diseases who are under)17.7 (going immunosuppressive)]TJ
0.0573 Tw T*
(therapy are highly susceptible to cytomegalovirus reactiva-)Tj
-0.0032 Tw T*
(tion. Further studies, including longitudinal analysis of viral)Tj
0.02879 Tw T*
(load and longer followup to fully elucidate the incidence of)Tj
0.02499 Tw T*
[(clinically significant CMV)-257.3 (diseases, should be conducted.)]TJ
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 259.1616 Tm
[(1.)-875.1 (W)79.9 (ard MM, Pyun E, Studenski S. Causes of death in systemic lupus)]TJ
1.675 -1.25 Td
[(erythematosus. )54.8 (Arthritis Rheum 1995;38:1492-9.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Bulpitt KJ, Brahn E. Systemic lupus erythematosus and concurrent)]TJ
1.675 -1.25 Td
[(cytomegalovirus vasculitis: diagnosis by antemortem skin biopsy)64.8 (. )]TJ
0 -1.25 TD
(J Rheumatol 1989;16:677-80.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Ikura )36.8 (Y)128.9 (, Matsuo )17.7 (T)74 (, Ogami M, et al. Cytomegalovirus-associated)]TJ
1.675 -1.25 Td
(pancreatitis in a patient with systemic lupus erythematosus. )Tj
T*
(J Rheumatol 2000;27:2715-7.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Garcia-Porrua C, Gonzalez-Gay MA, Perez de Llano LA, )]TJ
1.675 -1.25 Td
(Alvarez-Ferreira J. Fatal interstitial pneumonia due to)Tj
T*
(cytomegalovirus following cyclophosphamide treatment in a patient)Tj
T*
(with systemic lupus erythematosus. Scand J Rheumatol)Tj
0 Tc 0 Tw T*
(1998;27:465-6.)Tj
-0.00011 Tc 0.02499 Tw 31.325 71.921 Td
[(5.)-875.1 (Aglas F)79.7 (, Riner F)79.7 (, Hermann J, et al. Interstitial pneumonia due to)]TJ
1.675 -1.25 Td
(cytomegalovirus following low-dose methotrexate treatment for)Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:291-2.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Fraenkel G, Ross B, )17.7 (W)79.9 (ong H-C. Cytomegalovirus retinitis in a)]TJ
1.675 -1.25 Td
(patient with rheumatoid arthritis being treated with combination)Tj
T*
[(immunosuppressive therapy)64.8 (. Retina 1995;15:169-70.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Rider JR, Ollier )17.7 (WER, Lock RJ, Brookes ST)73.9 (, Pamphilon DH.)]TJ
1.675 -1.25 Td
(Human cytomegalovirus infection and systemic lupus )Tj
T*
(erythematosus. Clin Exp Rheumatol 1997;15:405-9.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Bendiksen S, )17.7 (V)110.8 (an Ghelue M, Rekvig OP)110.7 (, Gutteber)17.7 (g )17.7 (T)74 (, Haga H-J,)]TJ
1.675 -1.25 Td
[(Moens U. )54.8 (A)-220.1 (longitudinal study of human cytomegalovirus serology)]TJ
T*
(and viruria fails to detect active viral infection in 20 systemic lupus)Tj
T*
(erythematosus patients. Lupus 2000;9:120-6.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Hochber)17.7 (g MC. Updating the )54.8 (American College of Rheumatology)]TJ
1.675 -1.25 Td
(Revised Criteria for the classification of systemic lupus )Tj
T*
[(erythematosus [letter]. )54.8 (Arthritis Rheum 1997;40:1725.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Bohan )54.8 (A, Peter JB. Polymyositis and dermatomyositis \(first of 2)]TJ
2.175 -1.25 Td
(parts\). N Engl J Med 1975;292:344-7.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Bohan )54.8 (A, Peter JB. Polymyositis and dermatomyositis \(second of 2)]TJ
2.1381 -1.25 Td
(parts\). N Engl J Med 1975;292:403-7.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Masi )54.8 (A)110.8 (T)74 (, Rodnan GP)110.7 (, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, et al. Preliminary criteria for)]TJ
2.175 -1.25 Td
[(the classification of systemic sclerosis \(scleroderma\). )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1980;23:581-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Jennette JC, Falk RJ, )54.8 (Andrassy K, et al. Nomenclature of systemic)]TJ
2.175 -1.25 Td
(vasculitides. Proposal of an international consensus conference.)Tj
T*
(Arthritis Rheum 1994;37:187-92.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (T)69.9 (anaka N, Kimura H, Iida K, et al. Quantitative analysis of)]TJ
2.175 -1.25 Td
[(cytomegalovirus load using a real-time PCR assay)64.8 (. J Med )17.7 (V)59.8 (irol)]TJ
0 Tc 0 Tw T*
(2000;60:455-62.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction)]TJ
2.175 -1.25 Td
(monitoring reduces the incidence of cytomegalovirus disease and)Tj
T*
[(the duration and side ef)17.7 (fects of antiviral therapy after bone marrow)]TJ
T*
(transplantation. Blood 1995;86:2815-20.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Mori )17.7 (T)74 (, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive)]TJ
2.175 -1.25 Td
[(therapy for cytomegalovirus disease in patients under)17.7 (going )]TJ
T*
[(allogeneic bone marrow transplantation. Bone Marrow )17.7 (T)35 (ransplant)]TJ
0 Tc 0 Tw T*
(2000;25:765-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Mori )17.7 (T)74 (,)-0.1 ( Okamoto S, )17.7 (W)79.9 (atanabe R, et al. Dose-adjusted preemptive)]TJ
2.175 -1.25 Td
(therapy for cytomegalovirus disease based on real-time polymerase)Tj
T*
(chain reaction after allogeneic hematopoietic stem cell )Tj
T*
[(transplantation. Bone Marrow )17.7 (T)35 (ransplant 2002;29:777-82.)]TJ
-0.0118 Tw -2.175 -1.25 Td
[(19.)-875.1 (Ku )-36.8 (S-C, Y)110.8 (u)-0.1 ( )-36.9 (C-J, )-36.9 (Chang Y)110.8 (-L, Y)99.8 (ang )-36.8 (P-C. )-36.8 (Disseminated)]TJ
0.02499 Tw 2.175 -1.25 Td
(cytomegalovirus disease in a patient with systemic lupus )Tj
T*
[(erythematosus not under)17.7 (going immunosuppressive therapy)64.9 (. )]TJ
T*
[(J Formosa Med )54.8 (Assoc 1999;98:855-8.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (V)110.8 (asquez )17.7 (V)128.9 (, Barzaga RA, Cunha BA. Cytomegalovirus-induced)]TJ
2.175 -1.25 Td
(flare-up of systemic lupus erythematosus. Heart Lung )Tj
0 Tc 0 Tw T*
(1992;21:407-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Hayashi )17.7 (T)74 (, Lee S, Ogasawara H, et al. Exacerbation of systemic)]TJ
2.175 -1.25 Td
(lupus erythematosus related to cytomegalovirus infection. Lupus)Tj
0 Tc 0 Tw T*
(1998;7:561-4.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Mori, et al: CMV)-257.3 (in collagen disease)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1351)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>stream
8;Z\7$Z
rd](mC10PkIh@<&WuhRXo;]0\+c]qc>*X4!(aBHMi6,a/@r`
kY$7]MD*_Pj7h_*%O_8G2=(Z`5>]l8^bok#2^ti+oLLj*&?BdIn4rRj!Z.
M5o#KLcHhrHfR9&]'G0>g7Sm*DQ=<*+NM!@t[eHZM4.=tas_K4M/p&?`c:^1rkA
.'7DpXrZXa%L3\#lsdEkomupa"r9KM1/:s04-LWe)EtMQMtn9!>N5@oa/77##LHU;
>qe)MmhXo=@8Hoe6ZV!+30]VMU.WQ%!4?S
QAEUl/rr$3'>C'E8:+il):tNE>3r-LN1P$D5.Z;E@jnmVTk3O`X5u
HluR\X;eP^NVAO/2k#YiM(J#(a^;888%#]Xa2N#nS'7m19RF=d&T%[Qh]"AgXPrm,
=''sXi[sIb@*dMEFPPJSqhlfQm1C]bO&*%@rc#Qs]FCQH?NU9C&Hnm~>
endstream
endobj
15 0 obj
[/Indexed/DeviceRGB 255 14 0 R]
endobj
14 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
85 0 obj
<>
endobj
39 0 obj
<>
endobj
44 0 obj
<>
endobj
35 0 obj
<>
endobj
78 0 obj
<>
endobj
97 0 obj
<>
endobj
34 0 obj
<>
endobj
69 0 obj
<>stream
HUiPSY~K)$ң"*-hk(( "M#H$"Q@Fp)]FiwDQztfZҗYΟ?S[N.Y[a8;mٶ-,4tq /^,O{a;̳b<fdLb[✭5õ֡_ԿI6_eeЖ
fÈ}{F8Uv씏roߍH,-1ojOC(Lv~O(%Do/ 5W|Q%~b@̋IDxQ
O"HJd|^^|z2' bA ^$ApK`0G,c
[i
.Xei:,;=]q)X&fCߑYKX߲u+lmT6ogl;nbK$g}2a3*Υ٫g]@;ih1=8'pEsrtWWk/c X߽&"ԡso=JkV$*eE FqI8;-WSS%y#8tF
S>ZhvtRP(
=8& oyߌNGƮQ}d":W۾93N~6Bd#/}Y웄"8B)Sf\}Ƨ`ƻ yiFdBoһѫS|.M]ydpN-Ur3Gx'-gh$nh|a??q"+^iȪZ^,UtkxUq4h/r29qhL7,i)/)Cv%Kr !bA茜dH}ER(qV.8jzvUET^9a@W'r`&NSq)1GbO_+pāN^XY.Vd
SPD;c㰬9yT,f']\/ы\D
*Ed81hF+P_hiX~H{'zr
mq)mⱒѸ[T\o`'qעtP%?jd֔>ŝv~$I
<8-"Я)ܺ(1>E$4/&Xm$ŵP#TY9p
U94LwS"lf4e~g'\V9JoѦ&}d`h/t]x;)%_*f2N~̂3{ļά
BMw,8dE^N)*,> T3bq
1~i{|='^#>